Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × balixafortide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 2 Breast Neoplasms 2 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Advanced Breast Cancer 1

Interventions

Fulvestrant 17 Letrozole 9 Anastrozole 7 Capecitabine 5 olaparib 4 Docetaxel 4 pyrotinib 3 palbociclib 3 Vinorelbine 3 Paclitaxel 3 Goserelin 3 Aromatase Inhibitors 3 trastuzumab deruxtecan 2 sacituzumab govitecan 2 exemestane 2 eribulin 2 dalpiciclib 2 Trastuzumab 2 FCN-437c 2 Dasatinib 2 Alpelisib 2 Albumin-Bound Paclitaxel 2 vandetanib 1 talazoparib 1 sonidegib 1 ribociclib 1 neratinib 1 liposomal doxorubicin 1 irinotecan sucrosofate 1 entinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04826016 2023-03-20

POLTER

MedSIR

Phase 1/2 Withdrawn

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡